ArticleFrontiers in oncology2026

Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation.

Caroline Foxton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.